XOM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Exxon Mobil Corp (XOM) is not a strong buy for a beginner, long-term investor at this moment. While there are positive catalysts such as increased oil prices due to geopolitical tensions and favorable analyst upgrades, the company's recent financial performance shows declining revenue, net income, and EPS. Technical indicators suggest a neutral to slightly bearish trend, and there are no strong proprietary trading signals to support immediate action. Given the pre-market price drop of -3.78%, it is better to hold and reassess once the market stabilizes.
The MACD is negative and contracting (-2.106), indicating bearish momentum. RSI is neutral at 36.936, and moving averages are converging, showing no clear trend. Key support levels are at $148.652 and $143.889, with resistance at $156.36 and $164.069. Pre-market price is $146.25, which is below the first support level, suggesting potential further downside.
Increased oil prices due to geopolitical tensions (Iran conflict).
Analyst upgrades with higher price targets, including BNP Paribas raising the target to $
Historical ceasefire agreement between Israel and Lebanon, potentially stabilizing the Middle East region.
Pre-market price drop of -3.78%.
Declining financial performance in Q4 2025, with revenue, net income, and EPS all down YoY.
No significant hedge fund or insider trading activity.
Technical indicators suggest a neutral to bearish trend.
In Q4 2025, revenue dropped to $80.04 billion (-1.26% YoY), net income fell to $6.5 billion (-14.57% YoY), and EPS declined to $1.53 (-11.05% YoY). However, gross margin increased to 22.08% (+3.76% YoY), indicating some operational efficiency.
Analysts are generally positive on XOM, with multiple upgrades and price target increases. BNP Paribas upgraded the stock to Neutral with a $165 target, citing higher oil prices due to geopolitical tensions. Other analysts like RBC, Jefferies, and JPMorgan have raised price targets, but some firms like TD Cowen and Piper Sandler have lowered targets due to weaker-than-expected Q1 performance and volatility.
